Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | TACR2 | P21452 | 4/20 | 0.44 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355427 | 1.00 | ACKR3 (0.52) | ACKR3CAPN1HRH2HRH1SIGMAR1 | |
| SCHEMBL3356191 | 0.87 | ACKR3 (0.51) | ACKR3HRH2HRH1TACR2 | |
| SCHEMBL3356195 | 0.87 | ACKR3 (0.51) | ACKR3HRH2HRH1TACR2 | |
| SCHEMBL13496161 | 0.83 | CAPN1 (0.55) | ACKR3CAPN1CAPN2 | |
| SCHEMBL3355440 | 0.78 | UTS2R (0.39) | CAPN1HRH2HRH1FAAHDRD3 | |
| SCHEMBL3360397 | 0.78 | ACKR3 (0.53) | ACKR3CAPN1SIGMAR1CAPN2 | |
| SCHEMBL3360393 | 0.78 | ACKR3 (0.53) | ACKR3CAPN1SIGMAR1CAPN2 | |
| SCHEMBL13496112 | 0.77 | P2RX7 (0.54) | ACKR3TACR2 | |
| SCHEMBL3361016 | 0.77 | ACKR3 (0.46) | ACKR3CAPN1HRH2HRH1SIGMAR1 | |
| SCHEMBL24838800 | 0.76 | EPHX2 (0.45) | ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036122-A1 | CLEAVAGE AGENT SELECTIVELY ACTING ON SOLUBLE ASSEMBLY OF AMYLOIDOGENIC PEPTIDE OR PROTEIN | APP, BACE1, IAPP | ACKR3 2018/4885CAPN1 207/4885HRH2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.